Targeting Von Willebrand Factor to improve treatment for ischemic stroke
A novel thrombolytic targeting Von Willebrand Factor (VWF) to treat ischemic stroke
This study is exploring a new way to help people who have had an ischemic stroke by using a special treatment that targets a protein involved in blood clotting, aiming to safely and effectively break up clots in the brain and improve recovery, especially for those with larger blockages.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10887485 on NIH RePORTER |
What this research studies
This research investigates a new approach to treat ischemic stroke by targeting Von Willebrand Factor (VWF), a protein that plays a crucial role in blood clot formation. The study aims to develop a thrombolytic agent that can effectively dissolve clots in patients experiencing acute ischemic stroke, particularly those with large vessel occlusions. By focusing on the unique properties of VWF, the research seeks to enhance the safety and efficacy of stroke treatments compared to the currently used drug, rtPA. The methodology involves preclinical models to evaluate the effectiveness of this novel treatment in dissolving arterial clots and improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients experiencing acute ischemic stroke, particularly those with large vessel occlusions.
Not a fit: Patients who have experienced hemorrhagic strokes or those who do not present with acute ischemic stroke may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a safer and more effective treatment option for patients suffering from ischemic stroke.
How similar studies have performed: While the approach of targeting VWF is innovative, similar strategies in thrombolytic therapy have shown promise in preliminary studies, indicating potential for success.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Nimjee, Shahid — Ohio State University
- Study coordinator: Nimjee, Shahid
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.